Utilization of 17-gene biopsy-based genomics scores in treatment decisions for low- to intermediate-risk patients with prostate cancer.

Abstract

e627 Background: Patients with prostate cancer are faced with many different treatment options for their disease. A biopsy-based 17-gene genomic analysis is clinically validated as a predictor of favorable pathology and is used in our practice to aid men considering Active Surveillance in lieu of definitive treatment for their low- to intermediate-risk prostate cancer. We analyzed the treatment decisions made after receiving the Genomic Prostate Score (GPS) results of this test. Methods: We identified 77 patients between 2013 to 2015 from our practice who received Genomic Prostate Score results. We characterized their demographics, NCCN criteria both before and after the test, their Genomic Prostate Score (GPS), chance of favorable pathology, and treatment decision after the test. Results: Average age of the group electing surveillance after the genomic test was 61 years versus 65 in the group electing treatment (p=0.04). Average GPS in the surveillance group was 20 versus 28 in the treatment group (p=0.03). Average percent chance of favorable pathology was 80% in the surveillance group versus 63% in the treatment group (p<0.001). Conclusions: Biopsy-based genomics analysis can be a helpful tool for patients and practitioners who are evaluating candidacy for an Active Surveillance regimen versus definitive treatment for low- to intermediate-risk prostate cancer. [Table: see text]